Navigation Links
CLAAD Lauds Signature Therapeutics' R&D Efforts To Reduce Prescription Drug Abuse
Date:7/12/2013

WASHINGTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications. 

More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010, prescription drug overdoses took the lives of 22,134 Americans.[2] Since 2009, CLAAD has called for private-sector research into novel technologies to reduce prescription drug abuse. 

Michael Barnes, executive director of CLAAD, said, "Signature Therapeutics has distinguished itself in a growing market for safer medications by thinking big."

Signature Therapeutics is creating novel innovations, including "prodrugs," which would resist common methods of drug abuse, such as melting and injecting, crushing and snorting, or chewing before swallowing.  The company's pills are designed to be bioactivated, meaning that when taken by mouth, enzymes in the gastrointestinal tract trigger the release of the active ingredient.  Administered in any other way, a pill would not produce euphoria or any other significant effect.

Signature Therapeutics intends to apply its prodrug technology beyond opioids to other classes of commonly abused medications that lack safety features, such as stimulants used to treat attention-deficit disorder. Opioid pain relievers are the most commonly abused prescription drugs, but the abuse of tranquilizers, stimulants, and sedatives is also harmful and prevalent.[3]  In 2011, the anti-anxiety medication alprazolam was the most commonly found drug in overdose cases in Georgia, according to an analysis of autopsies.[4]  A study at the University of Kentucky found that out of 1,811 undergraduates, 34 percent reported improper use of stimulants.[5]

"Signature Therapeutics is the only company that I am aware of that is developing abuse-deterrent medications in a variety of drug classes," Barnes said.

Wes Sterman, CEO of Signature Therapeutics, said, "We are thrilled that CLAAD has recognized our commitment to raising the bar for abuse resistance."

About the Center for Lawful Access and Abuse Deterrence
CLAAD coordinates efforts to prevent prescription drug fraud, diversion, and abuse while advancing patient access to high-quality medical care. Follow @claad_coalition.

About Signature Therapeutics, Inc.
Signature Therapeutics is a privately-held biopharmaceutical company focused on creating best-in-class abuse-resistant prescription medications.


[1] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[2] http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html
[3] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[4] http://www.mcduffieprogress.com/article_4607.shtml
[5] http://www.schumer.senate.gov/record.cfm?id=344041  


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Petitions FDA To Reject Opioid Medications Without Safety Features
2. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
5. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
6. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
7. CLAAD Names Eagle Advancement Institute as Honoree of Top 5 Technologies To Reduce Prescription Drug Abuse
8. CLAAD Warns of Increase in Prescription Drug Overdoses
9. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
10. PPTA Applauds Preserving Access to Orphan Drugs Acts
11. CHPA Lauds Vermonts Adoption of HB 522
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 Serve You Rx Vermont, LLC, a wholly ... You), based in Milwaukee, Wisconsin , has ... in Middlebury, Vermont , from Pharmacy Health ... so it was perfect timing for this opportunity to present ... Serve You. "Like us, NEMOP has a high-touch service model, ...
(Date:3/22/2017)... 22. März 2017   VWR ... tätige Anbieter von Produkten und Dienstleistungen für ... von EPL Archives Inc. bekannt, eines internationalen ... im kompletten Zyklus regulierter Forschung, Entwicklung und ... Speicherung von Dokumenten und Zusatzdienstleistungen zur Seite ...
(Date:3/22/2017)... March 22, 2017 TapImmune, Inc. ... in the development of innovative peptide and gene-based ... disease, today announced that it will participate in ... Dr. Glynn Wilson , Chairman and CEO ... company,s business, clinical pipeline and partnering opportunities for ...
Breaking Medicine Technology:
(Date:3/22/2017)... Adelaide, Australia (PRWEB) , ... March 23, 2017 , ... ... As a nurse by profession, author Joy Nugent was inspired to write the book ... work came from her inward desire to make sense of what she was experiencing ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... Bay Area providing insurance assistance, financial planning, and related services to residents of ... International to promote awareness of threatened species and wild lands. , Endangered Species ...
(Date:3/22/2017)... California (PRWEB) , ... March 22, 2017 , ... Old ... British boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained with ... light welterweight title in 2011. He has racked up an impressive number of wins ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... digital and print media enterprise focused on cancer patients, cancer centers and advocacy ... a special 12-part educational video series, “No Ifs, Ands, or Butts,” that focuses ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... plan to cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 individuals ... located on the X chromosome, and almost exclusively strikes females. Following a ...
Breaking Medicine News(10 mins):